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pooled analysis
Kaitlin Rainwater-Lovett, Isabel Rodriguez-Barraquer, Derek AT Cummings and Justin Lessler*Abstract
Background: The plaque reduction neutralization test (PRNT) remains the gold standard for the detection of
serologic immune responses to dengue virus (DENV). While the basic concept of the PRNT remains constant, this
test has evolved in multiple laboratories, introducing variation in materials and methods. Despite the importance of
laboratory-to-laboratory comparability in DENV vaccine development, the effects of differing PRNT techniques on
assay results, particularly the use of different dengue strains within a serotype, have not been fully characterized.
Methods: We conducted a systematic review and pooled analysis of published literature reporting individual-level
PRNT titers to identify factors associated with heterogeneity in PRNT results and compared variation between
strains within DENV serotypes and between articles using hierarchical models.
Results: The literature search and selection criteria identified 8 vaccine trials and 25 natural exposure studies
reporting 4,411 titers from 605 individuals using 4 different neutralization percentages, 3 cell lines, 12 virus
concentrations and 51 strains. Of 1,057 titers from primary DENV exposure, titers to the exposure serotype were
consistently higher than titers to non-exposure serotypes. In contrast, titers from secondary DENV exposures
(n = 628) demonstrated high titers to exposure and non-exposure serotypes. Additionally, PRNT titers from different
strains within a serotype varied substantially. A pooled analysis of 1,689 titers demonstrated strain choice accounted
for 8.04% (90% credible interval [CrI]: 3.05%, 15.7%) of between-titer variation after adjusting for secondary exposure,
time since DENV exposure, vaccination and neutralization percentage. Differences between articles (a proxy for
inter-laboratory differences) accounted for 50.7% (90% CrI: 30.8%, 71.6%) of between-titer variance.
Conclusions: As promising vaccine candidates arise, the lack of standardized assays among diagnostic and research
laboratories make unbiased inferences about vaccine-induced protection difficult. Clearly defined, widely accessible
reference reagents, proficiency testing or algorithms to adjust for protocol differences would be a useful first step in
improving dengue PRNT comparability and quality assurance.Background
The re-emergence and geographic expansion of dengue
virus (DENV) over the past several decades has resulted
in the infection of 50–500 million individuals each year
[1,2]. Several rapid diagnostic tests and enzyme-linked
immunosorbent assays have been developed for the
detection of serologic immune responses to DENV
exposure [3], but the plaque reduction neutralization
test (PRNT) remains the gold standard. The PRNT
requires antibodies to neutralize and prevent virions* Correspondence: jlessler@jhsph.edu
Department of Epidemiology, Johns Hopkins Bloomberg School of Public
Health, Baltimore, Maryland, USA
© 2012 Rainwater-Lovett et al.; licensee BioMe
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumfrom infecting cultured cells, and is believed to represent
a protective antibody response. While the basic concept
of the PRNT remains constant, this test has evolved
in multiple laboratories throughout the world since its
development [4], introducing variation in methods that
may influence the comparability of results. For example,
cell type, virus passage, and the use of complement were
previously identified as sources of variation and had
varying effects between serotypes [5]. Additionally,
higher plaque neutralization levels (e.g., 90% vs. 50%)
have demonstrated less sensitivity [6].
Researchers and the World Health Organization’s
(WHO) Task Force on Clinical Trials of Dengue Vaccinesd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the use of reference sera or proficiency panels [7-9].
Recently, Roehrig et al. (2008) and the WHO (2009)
recommended specific dengue PRNT guidelines to
encourage standardization across laboratories for com-
parison of DENV vaccine trials [7,10,11]. As efforts to
develop DENV vaccines expand, more detailed character-
izations of antibody responses and factors influencing
the measurement of these responses are essential.
Although several vaccine candidates are under develop-
ment, comparisons between laboratories will be difficult
without relatively standardized laboratory materials and
methods [12] or algorithms to control for variations in
protocol. Examples of this variation include the addition
of complement or reporting sera dilutions before or after
the addition of virus. How different strains relate to one
another with respect to antibody cross-neutralization has
implications for the type of strains to be included in vac-
cine suspensions, whether a global or a region-specific
vaccine should be used, as well as future research efforts
after the development of a successful vaccine.
The objectives of this study were to characterize the
extent of variation in laboratory materials and methods
and the effects of this variation on PRNT titers using
published data. Here, we present a systematic review
of literature reporting individual-level PRNT titers to
identify factors associated with heterogeneity in PRNT
results and compare variation between strains within
DENV serotypes and between articles (to capture potential
inter-laboratory differences) using hierarchical models.
Methods
Search strategy and selection criteria
A systematic review was conducted during May-June
2009 using the PubMed and ISI Web of Knowledge 4.0
databases. Nine searches were performed using the
search term “dengue” and each of the following terms or
phrases: “antibody”, “serology”, “neutralization”, “serum
neutralization”, “prnt”, “infection history”, “previous
infection”, “longitudinal”, “antigenicity”, “vaccine”, “chi-
merivax” and “over time”. Articles were not restricted
by year of publication and included electronic, ahead-of-
print publications available in these databases. We did
not attempt to contact authors to obtain unpublished
PRNT titers. Abstracts were screened by two individuals
(KRL and IRB). Articles in languages other than English,
Spanish, and Portuguese and case reports or studies
of unusual patient populations were excluded. Unusual
patient populations were defined as individuals with co-
morbidities (e.g., cancer or organ failure) or neurologic
or central nervous system manifestations. Articles that
did not report dengue PRNT titers from humans or did
not state the time from dengue virus exposure to sera
collection were also excluded.Assessment
Each article was categorized based on the type of sera
samples collected. Natural exposure studies included
serological surveys (sera collected from individuals
regardless of dengue-like symptoms), infection studies
(sera collected in response to suspected dengue infection
as determined by study investigators or clinic/hospital
staff ), and human inoculation studies or accidental
inoculations in a laboratory setting. Vaccine studies were
defined as the collection of sera samples after enroll-
ment in a DENV vaccine study.
Data abstraction
Titers against each of the four DENV serotypes were
recorded from individual human subjects and classified
as natural exposure or vaccination. Titers reported in
tables or the text were abstracted while titers illustrated
in figures or requiring calculations by abstractors (e.g.,
an index score) were excluded. For the descriptive ana-
lysis, minimum titers (e.g., < 1:10 or < 1:40) were set to
zero and end-point titers that exceeded the maximum
dilution specified in the article, such as≥ 1:2560 or ≥
1:5120, were set to that value. The recorded materials
and methods used in PRNTs for each article included
dengue serotypes and strains, virus concentrations, cell
lines, and neutralization percentages (required percent-
age of plaques neutralized). If possible, authors were
contacted via email to obtain information on the DENV
strains used for PRNT; however, other raw data were
not requested.
The approximate time from infection or vaccination to
serum sample collection was categorized as unexposed,
acute (< 12 days), convalescent (12–30 days), late con-
valescent (30 days–1 year), and very late convalescent
(> 1 year) [13,14]. If a range of time was reported for
an individual sera sample (e.g., “Serum was collected
6–12 months following infection. . .”), the mid-point
between the minimum and maximum of the range was
used. If acute and convalescent sera samples were col-
lected but exact times from exposure or symptom onset
were not reported, acute samples were defined as 4 days
post-exposure and convalescent samples defined as
11 days post-exposure. If time from symptom onset
to serum sample collection was reported, 5 days were
added to account for the 4–6 day incubation period
of dengue virus [13] and make times since exposure
comparable between post-symptom onset and post-
exposure reports.
Previous DENV exposure or infection (primary/
secondary/tertiary) was based on explicit report by the
authors. “Confirmed” exposure to a specific serotype was
based on the reported contents of a vaccine in a vaccine
study or inoculation suspension in inoculation studies or
a polymerase chain reaction (PCR)-confirmed infection
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met, the probable infecting serotype was noted by
abstractors but not considered confirmed. For example,
probable infecting serotypes were commonly deduced by
an article’s authors from changes in serotype-specific
antibody titers or the most frequently detected serotype
during a recent epidemic.Pooled analysis
Pooled analyses were conducted using PRNT titers for
which a confirmed exposure serotype and exposure his-
tory (e.g., uninfected, primary, or secondary) could be
determined. These analyses aimed to characterize the
effects of strain choice and inter-laboratory variation on
PRNT titers after adjusting for laboratory methods,
exposure route and time since exposure. In the case of
primary exposure, it was assumed that natural
logarithm-transformed (log) titers depended on the ex-
posure serotype. For secondary exposure it was assumed
that log titers were independent of the exposure sero-
type, as indicated by the descriptive analysis of this data
and prior studies [15]. Pooled median log titers for each
exposure-testing serotype were calculated as a weighted
mean of strain-specific medians with the number of
strain-specific observations as weights.
We constructed log-linear hierarchical models to
characterize the effects of strain choice and inter-
laboratory variation on titers. Titers from individuals
who were simultaneously exposed to two or more sero-
types via multitypic vaccination were excluded. Titers
reported as less than the minimum dilution for that
particular article (e.g., <1:10 or <1:40) were treated as
censored observations distributed between 0.1 and the
minimum reported titer in that article. The maximum
reported titers were also treated as censored observa-
tions distributed between the maximum reported titer
and a 100-fold increase.
Model A assessed the effect of strain choice on log
PRNT titer. Categorical strain variables were assumed to
have random effects with mean zero and estimated vari-
ance. Strains originating in Thailand were used as the
reference strain within each serotype due to frequent
use in the abstracted articles and to provide geographic
consistency. Strains reported by only one article were
categorized as “Other” in each serotype. The strain cat-
egories were as follows: DENV1 – 16007, Hawaii, Other;
DENV2 – 16681, New Guinea B, New Guinea C, PR-
159, Other; DENV3 – 16562, H87, 116/00, Other;
DENV4 – 1036, H241, Dominica /814669, 4328S, Other.
Model B assessed the effect of inter-laboratory variation
on log PRNT titer. A random effect for article, with zero
mean and estimated variance, was included in this
model. Due to collinearities between the strain choiceand article, a model with effects for both strain and art-
icle was not evaluated.
In both models fixed effects were estimated to account
for infecting serotype and other factors that might affect
measured PRNT titer. For primary exposures, intercepts
were estimated for each exposure serotype-testing
serotype pair while for secondary exposures, intercepts
were estimated for each testing serotype. The following
were also evaluated during model selection: time since
exposure, neutralization percentage, cell line, virus
concentration and vaccination. Neutralization percent-
age estimates the effects of each 10% increase in
neutralization percentage after adjusting for other cov-
ariates. Similarly, the effect of vaccination is estimated
with reference to individuals with natural exposure after
adjusting for other covariates. Time since exposure was
treated as an ordinal variable using categories described
above with unexposed sera as the reference category.
All models were fit using Monte Carlo Markov Chain
(MCMC) methods in OpenBUGS [16] and the R Statis-
tical Package (version 2.10, R Development Core Team,
Vienna, Austria). Standard non-informative priors were
used for all fixed effects and estimated variance compo-
nents. For each model, three chains of 10,000 iterations
were run. The final 5,000 iterations of all chains were
combined to estimate the posterior distribution of
parameters. Models were selected based on minimizing
the deviance information criteria (DIC). The mean of
the posterior distribution is reported as the parameter
estimate, and 90% credible intervals report the range
between the 5th and 95th percentiles of the posterior dis-
tribution. Convergence was assessed by examination of
the MCMC chains and R-hat values for all estimated
parameters of <1.1 [17]. Full specifications of the models
are in Additional File 1.
Results
The literature searches yielded 777 articles. Eighty-seven
articles were eliminated after abstract screening and 658
additional articles were eliminated after full text review
(Figure 1). Of the 17 articles excluded due to non-
English/Spanish/Portuguese language, the languages of
publication were Chinese (n = 2), Danish (n = 1), French
(n = 6), German (n = 5), and Japanese (n = 3). Sources of
variation among the 32 articles meeting the inclusion
criteria included geographic variation of the study popu-
lation, neutralization percentage, cell line, virus concen-
tration, and strain (Tables 1 and 2). The 32 articles
reported 4,411 PRNT titers from 605 human subjects
(Table 3). Twenty-five articles (78%) reported data from
natural exposure studies and eight (25%) described vac-
cine studies. Articles do not sum to 32 because one art-
icle reported titers resulting from vaccination and
natural exposure (Table 1) [18].
Figure 1 Article selection and inclusion/exclusion criteria. Articles do not sum to 32 as one report included multiple exposure routes and is
included in both exposure categories.
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time points following primary or secondary DENV
exposure and few reports described changes in titers due
to seroconversion (Figure 2). Of the 4,411 titers
abstracted, 318 titers were from sera of unexposed indi-
viduals, 175 from the acute phase after exposure, 742
from convalescence, 2,326 from late convalescence and
850 from very late convalescence. Primary DENV expo-
sures resulted in 2,248 (51%) titers, 832 (19%) titers were
from secondary exposure, 80 (2%) from tertiary expos-
ure, 318 (7%) from unexposed sera, and 933 (21%) from
individuals with unknown infection histories. The study
populations ranged from 1-year old children to 90-year
old adults residing in at least 12 countries, half of which
were in Asia (Table 1). Vaccination studies occurred
mainly in the United States (n = 5) but also in Thailand
(n = 2) and Australia (n = 1). Sun et al. (2009) reported
titers from the largest number of individuals (n = 71)
(Figure 2 and Table 3) [48].
Variation in laboratory methods
Twenty-nine articles (90%) reported DENV1 PRNT
titers, nine (28%) of which did not report the strains
used (Table 2). The Hawaii, 16007, and Mochizuki
strains were used in multiple articles and six additional
strains were reported in one article each (indicated by
“Other” in Tables 2 and 3). Of these 29 articles, three
(10%) tested multiple DENV1 strains. Three articles did
not test against DENV1 strains (indicated by “n/a”).
Seventeen strains of DENV2 were tested in thirty articles
and two articles (7%) reported PRNT titers against mul-
tiple strains. Titers against DENV2 strain 16681 were
reported most frequently (n = 7 articles) followed by
New Guinea C (n = 4), New Guinea B (n = 3), and PR-
159 (n = 2). Two articles did not report PRNT titersagainst DENV2 strains. Titers against DENV3 strains
were reported in 31 articles with strain H87 used in nine
articles (28%). Seventeen different DENV3 strains were
reported with two articles (6%) testing multiple DENV3
strains. Eight DENV4 strains were used in 27 studies
and one article reported testing multiple strains. H241
was used most frequently (n = 9 articles), followed by
4328-S (n = 3) and Dominica/814669 and 1036 reported
in 2 articles each.
The cell lines, neutralization percentages, and concen-
tration of virus added to the PRNT were highly variable
between articles (Table 1). Plaque-forming units (pfu)
and focus-forming units (ffu) (quantities of viral particles
differentiated by infection of neighboring cells in an
assay) varied widely and were combined with varying
volumes of sera. LLC-MK2 cells were used in fifteen arti-
cles (47%) while six and nine articles (19% and 28%)
reported using Vero or BHK-21 cells, respectively. Two
articles (6%) did not report the cell lines used and one
article reported using both BHK-21 and LLC-MK2 cells
for the purposes of comparison [31]. Twenty-three arti-
cles reported neutralization percentages of 50%, while
four articles reported 70%, two articles reported 80%,
and one article reported 90%. One article compared
neutralization percentages of 50% and 70% [31] and
three articles did not report the neutralization percent-
age used [27,30,43].
Patterns of reported PRNT titers in primary and
secondary exposure
Titers were excluded from the pooled analysis if the
exposure serotype was not reported (n= 786), if exposure
occurred via multitypic vaccine suspension (n= 944) or if
titers were from unexposed sera (n= 74), leaving 1,615 pri-
mary and secondary exposure titers. Among 987 titers
Table 1 Number of articles reporting subject and
laboratory characteristics stratified by exposure route
Vaccination Natural Exposure Total
Geographic location of study population
Asia 2 15 17
North America 5 11 15*
South America 0 1 1
Africa 0 0 0
Australia 1 0 1
Europe 0 2 2
Not reported 1 1 1*
Neutralization percentage
50 % 5 18 23
70 % 0 3 3
80 % 2 2 3*
90 % 0 1 1
Not reported 1 2 3
Cell line
BHK 0 9 9
LLC-MK2 5 11 16
Vero 3 4 6*
Not reported 0 2 2
Virus concentration (plaque-forming units [pfu] or focus-forming units [ffu]
per microliter [uL] or milliliter [mL])
10-20 pfu / 10 uL 0 1 1
10-20 pfu / 50 uL 0 2 2
15-25 pfu / 25 uL 0 2 2
20-30 pfu / 12.5 uL 0 2 2
40-80 pfu / 100 uL 0 1 1
50 pfu / 150 uL 3 4 7
107 pfu / mL 2 0 2
25-50 pfu 0 1 1
50 pfu 0 1 1
320 pfu 0 1 1
100 ffu / 90 uL 0 1 1
800 ffu 1 1 1*
Not reported 2 8 10
* indicates articles do not sum in row as Vasilakis et al. [18] reported titers
from vaccination and natural exposure.
Table 2 Number of articles reporting specific strains
stratified by exposure route
Vaccination Natural Exposure Total
DENV1 strain
Hawaii 1 8 9
16007 2 4 6
Mochizuki 0 2 2
Other 2 4 5*
Not reported 2 7 9
n/a 1 2 3
DENV2 strain
New Guinea B 0 3 3
New Guinea C 1 3 4*
16681 3 6 8*
PR-159 1 1 2
Other 2 4 6
Not reported 2 6 8
n/a 0 2 2
DENV3 strain
H87 0 9 9
116/00 0 2 2
16562 2 4 6
CH53489 2 0 2
PR-6 0 2 2
Other 1 3 4
Not reported 2 7 9
n/a 1 0 1
DENV4 strain
H241 1 9 9*
Dominica 1 1 2
4328-S 0 3 3
1036 2 0 2
Other 2 2 4
Not reported 2 6 8
n/a 1 4 5
* indicates articles do not sum in row as Vasilakis et al. [18] reported titers
from vaccination and natural exposure.
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were consistently high, and there was low reactivity to
non-exposure serotypes (Figure 3). When sera from con-
firmed DENV1 exposures were tested against DENV1
strains, the pooled median log titer was 4.75 (standard
error [SE]: 0.049) while testing DENV1-exposed sera with
DENV2, DENV3, and DENV4 strains produced pooled
median log titers ranging from 0.14-1.51. Homotypic test-
ing with DENV2, DENV3, and DENV4 resulted in pooledmedian log titers of 4.98 (SE: 0.103), 4.45 (SE: 0.119) and
5.49 (SE: 0.118), respectively, while heterotypic testing
produced titers ranging from 0–0.288.
In contrast, secondary DENV exposures (n = 628
observations) produced high heterotypic titers, and test-
ing with the exposure serotype did not always generate
the highest PRNT titer (Figure 4). Pooled median log
titers were highest when tested against the exposure
serotype for DENV1 (6.89 [SE: 0.094]) and DENV2 (7.36
[SE: 0.042]) compared to non-exposure serotypes. For
DENV3 exposure, however, the pooled median log titer
Table 3 Summary of articles meeting the inclusion criteria
Author & Publication Year
(Reference)
Study Population Age [years] # Subjects
(# Titers)
Days Post-
Exposure
Neut.
%
DENV1 strains DENV2 strains DENV3 strains DENV4 strains
Natural Exposure Studies
Russell et al. 1967 [19] Thailand, USA children, adults 7 (28) 17-28 50 – – – –
Sukhavachana et al. 1969 [20] – – 2 (16) 7, 14 50 Hawaii New Guinea C H87 H241
Scott et al. 1972 [21] Puerto Rico – 3 (11) 11-20 50 Hawaii PR-109 H87 23751
Russell and McCown 1972 [22] Puerto Rico, Tahiti – 5 (30) 21 50 n/a n/a H87, 21153, PR-6,
PR-38, J-1007,
Tahiti-4
n/a
Halstead 1974 [23]* USA adults 9 (36) 15341-17532 50 16007 16681 16562 4328-S
Papaevangelou and Halstead
1977 [24]*
Greece adults 45 (180) 16436 50 16007 16681 16562 4328S
Fujita and Yoshida 1979 [25] Japan 45-74 9 (36) 12419 50 Mochizuki, Hawaii Trinidad 1751 H87 H241
Scott et al. 1976 [26] Thailand children 6 (48) 3-67 50 – – – –
van Peenen et al. 1978 [27] Indonesia 1-18 4 (32) 7, 14 – – – – –
Okuno et al. 1980 [28]* Thailand 1-13 20 (160) 1-13 50 Hawaii New Guinea B H87 H241
Fukunaga et al. 1983 [29]* Japan 28-55 9 (36) 2-13 50 Hawaii New Guinea B H87 H241
Okuno et al. 1983 [30] Japan adults 11 (51) 1826-14610 – Hawaii, Mochizuki New Guinea B H87 H241
Sangkawibha et al. 1984 [15]* Thailand 1-8 8 (60) 0-17 50 16007 16681 16562 4328-S
Morens et al. 1985 [31] Puerto Rico – 24 (267) 0-70 50 & 70 CV.1636 / 77 PR-159 PR-6 n/a
Rosen 1986 [32]* Greece, Pacific
Islands, USA
42-60 68 (268) 7-16436 90 Hawaii New Guinea C H87 H241
Kliks et al. 1989 [33]* Thailand children 10 (40) 0 50 – D80-616 – –
Kuno et al. 1993 [34] Puerto Rico 4-50 9 (79) 0-83 50 – – – –
Graham et al. 1999 [35]* Indonesia 4-9 17 (131) 0, 10-361 70 16007 16681 16562 1009
Yamada et al. 2003 [36] Japan – 37 (71) 2-44 50 – – – –
Alvarez et al. 2006 [37]* Cuba – 43 (371) 3-21, 517-834 50 Angola A15/81, I348600 116/00 Dominica / 814669
Alvarez et al. 2008 [38]* Cuba – 20 (140) 515 50 n/a n/a 116/00, 118/00,
140/00, 167/01,
557/01, 21/02,
Puerto Rico
n/a
Lai et al. 2008 [39]* Taiwan – 7 (32) 7-14 70 Hawaii New Guinea C H87 H241
da Silva-Nunes et al. 2008 [40] Brazil 5-90 20 (120) 0, 274 50 – – – n/a
Crill et al. 2009 [41]* Taiwan,
Puerto Rico
– 12 (48) 6-18 80 56BC94 / 95 16681 116RC1396 H241
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Table 3 Summary of articles meeting the inclusion criteria (Continued)
Vaccination Studies
Summers et al. 1984 [42]* USA – 8 (16) 30, 180 50 n/a PR-159 n/a n/a
Rabablert et al. 2000 [43]* Thailand 18-35 8 (64) 0, 60 – 16007 16681 16562 1036
Rothman et al. 2001 [44] USA – 6 (48) 60, 180 80 Hawaii New Guinea C CH53489 Dominica / 814669
Kanesa-Thasan et al. 2003 [45]* USA 18-49 20 (397) 0, 28, 60, 120, 180 50 – – – –
Guy et al. 2004 [46] Thailand 4-14 16 (128) 273, 2009 50 16007 16681 16562 1036
Kitchener et al. 2006 [47] Australia 21-39 10 (40) 42 50 – – – –
Vasilakis et al. 2008 [18]*^ USA, unknown
location
18-50 61 (719) 42 vacc, 16 infect 80 OBS7690,
P72-1244
16681, 1349, IQT1950,
1328, P8-1407,
DakArA510, DakArA1247,
DakArA2022
FSP-032 H241, P75-125
Sun et al. 2009 [48] USA 18-45 71 (704) 28, 180, 208 50 45AZ5 S16803 CH53489 341750
“Neut. %” indicates neutralization percentage; “DENV#” indicates dengue virus serotype; “—” indicates unreported data; “n/a” indicates serotype was not tested, ^ indicates article contains titers from vaccination and
infection studies, * indicates article was included in the pooled analysis.
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Figure 2 Dengue virus (DENV) exposure timeline of PRNT titers included in this review. Articles above the timeline reported transitions
between exposure states while articles below reported single states. 1°, 2°, and 3° abbreviate primary, secondary, and tertiary exposures; “n”
indicates the numbers of individuals who contributed titers that met inclusion and exclusion criteria; “Days Post” indicates the number of days
between DENV exposure and serum collection.
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titers produced by DENV1 testing (5.63 [SE: 0.039]).
Secondary DENV4 exposures showed a similar trend of
high pooled median log titers against cross-serotypes,
but few observations (n = 16) yielded uninformative stat-
istical comparisons. As a result of these observations,
the PRNT titer resulting from testing after secondary ex-
posure was assumed to be independent of the secondary
exposure serotype in the hierarchical models.
For the hierarchical models, titers were excluded if
individuals were simultaneously exposed to more than
one serotype via multivalent vaccination (n = 948) or the
exposure serotype (n = 786), testing strain (n = 127) or
exposure history (n = 911) were not reported. These cri-
teria resulted in a total of 1,639 titers representing 929
individuals and 16 articles. The pattern of elevated titer
against the exposure serotype was preserved in both
models, with higher PRNT titers in sera tested against
the exposure serotype compared to non-exposure sero-
types after adjusting for other covariates (Table 4). Forexample, using estimates from model A, primary expo-
sures to DENV2 tested against DENV2 result in an
absolute titer of 9.17 (90% CrI: 4.84, 16.9) after adjusting
for other covariates, whereas testing DENV2-exposed
sera with DENV3 strains produces an absolute titer of
0.22 (90% CrI: 0.11, 0.44).Strain dependence of reported PRNT titers
Among individuals with confirmed primary DENV expo-
sures, neutralization titers from each strain varied sub-
stantially within each serotype (Figure 3). For instance,
individuals with primary DENV3 exposure had variabil-
ity in unadjusted median log titers between strains ran-
ging from 2.89 (IQR: 2.30, 3.23) for strain CH53489 to
5.56 (IQR: 5.21, 6.75) for strain 16562. Median log titers
among individuals with secondary exposure also showed
variability between strains; however, stratification by
strain resulted in few observations and limited inference
(Figure 4).
Figure 3 Matrices of natural logarithm-transformed PRNT titers from primary DENV exposures stratified by strain. The “n” on the upper
right of each exposure column represents the number of titers, filled squares indicate the pooled median log titer for all strains within that
particular box, diamonds with crosshairs represent median log titers for strains, horizontal lines span the 25th-75th percentiles (interquartile
range), and vertical lines mark the 5th and 95th percentiles of the data.
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for 8.04% (90% CrI: 3.05%, 15.7%) of the variability in
the PRNT titers after adjusting for other covariates
(Table 4, Model A). While most strains produced rela-
tively small effects on titers in comparison to the refer-
ence strains, others yielded more significant changes.
Testing with DENV2 strain PR-159 and DENV4 strain
Dominica/814669 yielded titers that were 0.48 [90% CrI:
0.25, 0.85] and 0.32 [90% CrI: 0.16, 0.62] that of titers
from the respective reference strains, while DENV4
strain 4382-S produced 1.62-fold (90% CrI: 1.02, 2.55)
increase in titer compared to the reference strain
(Table 4, Model A). Additionally, accounting for strainin Model A reduced the effect of secondary exposure by
36-79% (Model A vs. B in Table 4).
Other drivers of variation in PRNT titers
Time since exposure demonstrated a characteristic pat-
tern of serologic response in both models, although we
were unable to estimate the effect of acute DENV expo-
sures due to a lack of titers fulfilling model inclusion cri-
teria (Table 4). In Model A, convalescent DENV
exposures (n = 339 titers) produced 8.51-fold (90% CrI:
5.47, 13.2) the mean titer of unexposed individuals
(n = 177), decreasing to 5.57-fold (90% CrI: 3.79, 8.24)
during late convalescence (n = 515) and 3.13-fold (90%
Figure 4 Matrices of natural logarithm-transformed PRNT titers from secondary infections stratified by strain. The “n” on the upper right
of each exposure column represents the number of titers, filled squares indicate the pooled median log titer for all strains within that particular
box, diamonds with crosshairs represent median log titers for strains, horizontal lines span the 25th-75th percentiles (interquartile range), and
vertical lines mark the 5th and 95th percentiles of the data.
Rainwater-Lovett et al. BMC Infectious Diseases 2012, 12:233 Page 10 of 15
http://www.biomedcentral.com/1471-2334/12/233CrI: 2.05, 4.81) during very late convalescence (n = 608).
Each 10% change in neutralization percentage resulted
in a 1.23-fold (90% CrI: 1.14, 1.33) change in titer
(Table 4, Model A). Interestingly, titers resulting from
vaccination (n = 433) were 0.91 (90% CrI: 0.70, 1.16) that
of titers from natural exposure (Table 4). Cell line and
virus concentration were evaluated as potential covari-
ates but did not explain additional variation among
titers as determined by increases in DIC values (data
not shown).
Variation between articles (a proxy for inter-laboratory
differences) produced 50.7% (90% CrI 30.8%, 71.6%) of
the variation in PRNT titers not accounted for by othercovariates (Table 4, Model B). Because of the association
between article and laboratory methods, it is not pos-
sible to quantify how much of this variation is due to
differences in strain and other aspects of the PRNT
methods while also accounting for article variation.
It is important to note that article-to-article variation
may be inflated by differences in study population and
other unmeasured covariates.
Discussion
This systematic review of human PRNT titers to DENV
demonstrated highly variable laboratory methods, par-
ticularly among viral strains. Despite analyzing 1,689
Table 4 Point estimates and 90% credible intervals (CrI) from the log-linear hierarchical models of PRNT titers
Model A Model B
Intercept Absolute Titer (90% CrI)
Primary exposure Testing serotype
Uninfected DENV1 0.42 (0.16, 1.17) 0.43 (0.15, 1.29)
DENV2 0.44 (0.15, 1.18) 0.43 (0.13, 1.35)
DENV3 0.44 (0.16, 1.24) 0.44 (0.14, 1.26)
DENV4 0.41 (0.14, 1.17) 0.42 (0.14, 1.19)
DENV1 DENV1 5.44 (2.91, 10.7) 15.1 (9.52, 23.8)
DENV2 0.59 (0.31, 1.14) 1.19 (0.75, 1.89)
DENV3 0.55 (0.28, 1.08) 1.17 (0.73, 1.85)
DENV4 0.13 (0.06, 0.27) 0.29 (0.17, 0.48)
DENV2 DENV1 0.13 (0.06, 0.25) 0.46 (0.26, 0.81)
DENV2 9.17 (4.84, 16.9) 26.1 (17.0, 40.9)
DENV3 0.22 (0.11, 0.44) 0.65 (0.38, 1.10)
DENV4 0.13 (0.06, 0.24) 0.37 (0.22, 0.63)
DENV3 DENV1 0.11 (0.05, 0.23) 0.36 (0.17, 0.77)
DENV2 0.13 (0.06, 0.27) 0.32 (0.16, 0.62)
DENV3 7.98 (3.96, 15.4) 32.6 (19.0, 55.2)
DENV4 0.11 (0.05, 0.26) 0.30 (0.14, 0.65)
DENV4 DENV1 0.22 (0.11, 0.48) 0.52 (0.24, 1.07)
DENV2 0.46 (0.21, 1.00) 0.98 (0.48, 1.99)
DENV3 0.30 (0.13, 0.69) 0.72 (0.37, 1.43)
DENV4 12.1 (5.93, 24.0) 29.8 (16.7, 52.4)
Testing serotype among secondary exposures
DENV1 26.5 (13.8, 53.8) 76.1 (43.0, 131)
DENV2 6.50 (3.26, 12.7) 17.6 (10.2, 30.3)
DENV3 5.46 (2.90, 10.4) 25.8 (15.3, 42.8)
DENV4 1.69 (0.79, 3.69) 2.63 (1.49, 4.57)
Fixed Effect Relative Titer (90% CrI)
10% increase in neutralization percentage 1.23 (1.14, 1.33)
Vaccination 0.91 (0.70, 1.16) 0.89 (0.85, 0.94)
Time category
Unexposed Reference Reference
1-11 days post-exposure (d.p.e.) 4.16 (2.57, 6.71) 2.86 (1.59, 5.01)
12-30 d.p.e. 8.51 (5.47, 13.2) 7.11 (4.46, 11.5)
31 -365 d.p.e. 5.57 (3.79, 8.24) 5.44 (3.68, 8.02)
>365 d.p.e. 3.13 (2.05, 4.81) 1.80 (0.98, 3.24)
Random Effect Relative Titer (90% CrI)
Testing serotype Testing strain
DENV1 16007 Reference
Hawaii 1.18 (0.79, 1.75)
Other DENV1 strains 0.97 (0.63, 1.50)
DENV2 16681 Reference
New Guinea B 0.90 (0.53, 1.53)
New Guinea C 0.64 (0.40, 1.00)
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Table 4 Point estimates and 90% credible intervals (CrI) from the log-linear hierarchical models of PRNT titers
(Continued)
PR-159 0.48 (0.25, 0.85)
Other DENV2 strains 0.90 (0.60, 1.31)
DENV3 16562 Reference
H87 0.76 (0.49, 1.15)
116/00 1.33 (0.91, 1.96)
Other DENV3 strains 0.62 (0.43, 0.90)
DENV4 1036 Reference
H241 0.73 (0.45, 1.17)
Dominica/814669 0.32 (0.16, 0.62)
4328-S 1.60 (1.02, 2.55)
Other DENV4 strains 1.13 (0.66, 1.88)
Variance Components Proportion of the total variance (90% CrI)
Strain 8.04% (3.05%, 15.7%)
Article 50.7% (30.8%, 71.6%)
Deviance Information Criteria 14910 14830
The two models account for variance in PRNT titers due to differences between strains (Model A) or articles (Model B). The average PRNT titer of sera collected
from individuals with specific characteristics can be calculated as the product of the exponential of the coefficients listed. For example, using estimates from
model A, the average titer for convalescent individuals with primary infections from DENV2, tested against DENV2 strain New Guinea B using a PRNT60 would be:
9.17 [primary DENV2 exposure, tested against DENV2] * 0.90 [tested against New Guinea B] * 1.236 [PRNT60] * 8.51 [12–30 days post-exposure] = 243, or 1:243.
Similarly, under the same conditions, secondary DENV2 exposure via vaccination would result in an average titer of 1:157 (6.50 [secondary DENV2 exposure, tested
against DENV2] * 0.90 * 0.91 [vaccination] * 1.236 * 8.51 = 157).
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difficult to ascertain given the heterogeneity in labora-
tory methods. The original report on the development
of a PRNT for DENV by Russell et al. (1967) was refer-
enced frequently in the articles reviewed here [4], some-
times as the sole description of PRNT methods.
However, most articles reported alterations to this proto-
col due to the identification of techniques or materials
enhancing the assay’s performance in their laboratories.
A large number of articles did not report information
such as neutralization percentage, cell lines, the use of
complement, and virus concentrations, making it impos-
sible to fully adjust for these factors. In addition to the
diverse array of materials and methods, heterogeneity in
PRNT titers can also be induced by volume of virus
added, serum dilutions prior to addition of virus, plaque
counting techniques such as accounting for plaque over-
lap, and titer calculations [7], which were rarely
described in the articles reviewed here.
Several additional factors may have influenced the
PRNT titers collected here and differences observed
between strains after adjusting for other factors in the
models. First, the study populations described in these
reports were from several different geographical areas
(Table 3), which may affect not only strains to which an
individual was exposed, but also strains against which
their serum was tested. Secondly, there is likely an asso-
ciation between the testing strains and primary or sec-
ondary exposure based on each study’s inclusion criteriaand laboratory methods. Lastly, the antibody response
elicited by different infecting strains may vary in quality,
duration and magnitude, highlighting antigenic differ-
ences between strains that call for further exploration.
For example, Asian dengue strains have been noted to
produce different serological reactions than American
strains [49]. This may explain why DENV2 strain PR-
159 and DENV4 strain Dominica/814669 produced rela-
tively lower titers than Thai references strains.
Strain variation produced differences in median log
titers within each serotype. After adjusting for several
covariates, the choice of strain accounted for approxi-
mately 8% of the variation in titers, while variation
between articles, which was used as a proxy for inter-
laboratory variation, explained half of the variation in
titers, suggesting comparability between laboratories is
currently quite poor. The use of reference strains alone
will not solve this issue, but the use of reference
reagents or proficiency panels would lend validity to
each laboratory’s results by offering a means of
quality assurance and allow each laboratory to compare
“in-house” materials and methods against a standard.
Alternatively, algorithms that control for protocol
variations would allow laboratories to continue with
their preferred materials and methods but would adjust
results for comparability.
Most often, PRNT titers are reported as the reciprocal
of the serum dilution that shows a 50% reduction in
the number of plaques produced by DENV exposure.
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neutralization percentages (e.g., PRNT60) have been used
to increase specificity and prevent the detection of
cross-neutralizing antibodies [18], but this must be
weighed against decreased sensitivity [6]. Upon inclusion
of neutralization percentage in the hierarchical model,
an increase in titer was observed with each 10% increase
in neutralization percentage. While we would expect a
decrease in titer with higher neutralization percentage
(e.g., 1:80 in PRNT50 versus 1:10 in PRNT60), this rela-
tionship may have been highly influenced by the few low
titers reported in studies using higher neutralization per-
centages (e.g. PRNT90) and the many low titers reported
in studies using PRNT50.
As titers were abstracted directly from the literature,
our results are limited by published data. Titers are
more likely to be reported and published if the findings
are unusual or significantly different from previous
reports. Also, relatively few titers (n = 177) were reported
from unexposed individuals. Prior exposure to DENV
was determined based on authors’ report, which may re-
sult in misclassification, and the primary exposures were
unknown among individuals with secondary exposures.
Original antigenic sin and variability in cross-reactive
responses may have large effects on neutralization
responses that are impossible for us to quantify without
knowledge of primary exposures [34]. Furthermore,
titers from individuals exposed to other flaviviruses were
not included in this review. The exposure history of
individuals to other flaviviruses was unknown in our
sample and cross-reactions with non-dengue flaviviruses
may be an additional factor to consider when analyzing
PRNT data. The data were inadequate to estimate sec-
ondary exposure-test serotype pair effects in addition to
effects for individual strains or articles. Lastly, the inclu-
sion of reports published in English, Spanish and Portu-
guese reduced the potential for geographic selection
bias, but may have excluded influential Asian studies.
Conclusions
By synthesizing data from multiple sources, this analysis
allows for between-laboratory and between-strain com-
parisons in addition to other factors that can influence
PRNT titer variation. In-house optimizations of the
PRNT that initially appear to produce minute changes
may combine to create large differences when compar-
ing results across multiple laboratories. These factors
may have a significant impact on the neutralization cap-
abilities of antibodies elicited in response to DENV
exposure, hindering the ability to decipher immune pro-
tection and infection history. Despite well-known proto-
col variations, inadequate descriptions of materials and
methods make inferential adjustments for these differ-
ences impractical. This requires improvement.While we believe the PRNT provides a correlate of
protection, the current methods do not take full advantage
of quantitative results and render informal categorization
of neutralization responses. Clinical endpoints will likely
be used to assess vaccine efficacy but discrepancies in
protection will require more thorough assessments of
neutralization titers. Systematic characterization of anti-
genic similarities between strains will help clarify which
strains are likely to induce immunogenicity and protection
against other strains, aiding in vaccine strain selection.
Nevertheless, as promising vaccine candidates arise, the
lack of standardized assays among diagnostic and research
laboratories will make unbiased inferences about vaccine-
induced protection difficult. Sources of variation have im-
portant implications for vaccine testing and comparability.
Prudent study design of a candidate vaccine will ensure
testing in multiple geographic locations by highly similar
materials and methods, but will immunogenicity of com-
peting manufacturers’ vaccines determined by differing
materials and methods be comparable? This has direct
consequences for clinical decision making and policy
guidelines. Establishing methods for inter-laboratory com-
parisons will help unravel the complex cross-reactions that
characterize dengue virus exposures.
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